Taysha Gene Therapies, Inc. Common Stock (TSHA) Stock Price

TSHAStock

$5.77+103.89%52W

Market Cap$1.88B

P/E—

PEG Ratio—

Div yield—

Beta1.22

TSHA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)6.07%

Price vs S&P 500 (4W)-1.71%

VGM Score47.65

Book Value / Share (Quarterly)$0.74

P/TBV (Annual)342.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)57.53%

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-7.91%

Net Profit Margin (TTM)-780.33%

EPS (TTM)$-0.38

10-Day Avg Trading Volume2.50M

EPS Excl Extra (TTM)$-0.38

EPS (Annual)$-0.34

ROI (Annual)-36.65%

Cash / Share (Quarterly)$0.96

Revenue Growth QoQ (YoY)171.27%

ROA (Last FY)-31.75%

Revenue Growth TTM (YoY)3.42%

EBITD / Share (TTM)$-0.38

ROE (5Y Avg)-3789.27%

Operating Margin (TTM)-782.50%

Cash Flow / Share (Annual)$-0.33

P/B Ratio9.19x

P/B Ratio (Quarterly)6.06x

Net Income / Employee (Annual)$-1,101,000

EV / Revenue (TTM)175.95x

Net Interest Coverage (TTM)-77.24x

ROA (TTM)-40.16%

EPS Incl Extra (Annual)$-0.34

Current Ratio (Annual)12.23x

Quick Ratio (Quarterly)13.84x

3-Month Avg Trading Volume2.89M

52-Week Price Return103.89%

Revenue / Employee (TTM)$75,500

Tangible BV / Share (Quarterly)$-0.26

P/S Ratio (Annual)199.21x

Asset Turnover (Annual)0.03x

52-Week High$7.30

EPS Excl Extra (Annual)$-0.34

CapEx CAGR (5Y)55.95%

26-Week Price Return18.00%

Quick Ratio (Annual)12.10x

13-Week Price Return-2.53%

Total Debt / Equity (Annual)0.20x

Current Ratio (Quarterly)14.04x

Enterprise Value$1.72B

Asset Turnover (TTM)0.04x

Book Value / Share Growth (5Y)-34.68%

Revenue / Employee (Annual)$98,700

Pretax Margin (Annual)-1115.27%

Cash / Share (Annual)$1.12

3-Month Return Std Dev67.87%

Net Income / Employee (TTM)$-1,311,900

ROE (Last FY)-44.14%

Net Interest Coverage (Annual)-65.37x

EPS Basic Excl Extra (Annual)$-0.34

Total Debt / Equity (Quarterly)0.23x

EPS Incl Extra (TTM)$-0.38

ROI (TTM)-46.41%

P/S Ratio (TTM)199.21x

Revenue / Share (Annual)$0.03

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)85.33%

Year-to-Date Return4.91%

5-Day Price Return-3.35%

EPS Normalized (Annual)$-0.34

ROA (5Y Avg)-73.00%

Net Profit Margin (Annual)-1115.27%

Month-to-Date Return-1.54%

Cash Flow / Share (TTM)$-2.76

EBITD / Share (Annual)$-0.34

Operating Margin (Annual)-1130.65%

LT Debt / Equity (Annual)0.20x

ROI (5Y Avg)-153.51%

LT Debt / Equity (Quarterly)0.23x

EPS Basic Excl Extra (TTM)$-0.38

P/B Ratio (Annual)6.10x

Pretax Margin (TTM)-780.33%

Book Value / Share (Annual)$0.87

Price vs S&P 500 (13W)-4.49%

Beta1.22x

Revenue / Share (TTM)$0.02

ROE (TTM)-56.07%

52-Week Low$2.71

vGradeF

gGradeB

mGradeB

vgmGradeC

TSHA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.11	-$0.13	-22.42%(-$0.02)
Q1 2026	May 6, 2026	-$0.10	-$0.11	-13.98%(-$0.01)
Q4 2025	Mar 19, 2026	-$0.10	-$0.07	+25.34%(+$0.02)
Q3 2025	Nov 4, 2025	-$0.09	-$0.09	-1.74%(-$0.00)
Q2 2025	Aug 12, 2025	-$0.07	-$0.08	-12.52%(-$0.01)

TSHA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.25

4.26

4.28

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	$24.36

About Taysha Gene Therapies, Inc. Common Stock

Taysha Gene Therapies develops AAV-based gene therapies for monogenic central nervous system diseases, targeting both rare and large patient populations. Its clinical-stage pipeline includes TSHA-102, a self-complementary AAV9 therapy delivered intrathecally for the treatment of Rett syndrome.